GENE ONLINE|News &
Opinion
Blog

2023-01-31| Special

J&J’s Market Value Plummets by $17 Billion After Appeals Court Denies Bankruptcy Escape

by Richard Chau
Share To
On January 30, a federal appellate court in Philadelphia dismissed the bankruptcy filed by the Johnson & Johnson (J&J) subsidiary in October 2021, ruling that the pharmaceutical giant cannot use a corporate bankruptcy to escape the liabilities stemming from lawsuits over its allegedly carcinogenic baby powder products.

The federal court’s ruling revives about 40,000 baby powder lawsuits that have once been put to a halt due to J&J’s creation of a new subsidiary and the subsequent bankruptcy filing by that newly formed company. Shares of J&J fell 3.7% on news of the ruling, wiping about $17 billion off their market value.

It's free! Log in now to read

LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
EVENT
Scroll to Top